Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Wheeler

Nurse Practitioner, Family Riverview, FL Nurse Practitioner

NPI 1467043604 CMS profile 9294896

11264 Boyette Rd, Riverview, FL 33569

Open in the dashboard

General payments

$45,165

355 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Wheeler of Riverview, FL is reported in the CMS Open Payments database as having received $45,165 across 355 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,259 74
2024 General $25,833 165
2023 General $10,194 68
2022 General $3,378 35
2021 General $500 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Wheeler
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ashley Wheeler were reported at $5,259. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ashley Wheeler Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $500 $124 $35–$379 $132
2022 $3,378 $141 $44–$430 $149
2023 $10,194 $154 $49–$476 $160
2024 $25,833 $165 $51–$504 $164
2025 $5,259 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $36,621 197 payments
  2. Spinal Simplicity, LLC $2,848 37 payments
  3. Painteq LLC $2,543 59 payments
  4. Boston Scientific Corporation $710 21 payments
  5. Abbott Laboratories $634 8 payments
  6. Globus Medical, Inc. $420 8 payments
  7. Vertos Medical, Inc. $378 7 payments
  8. SPR Therapeutics, Inc $363 5 payments
  9. Stryker Corporation $133 2 payments
  10. BIOTRONIK NRO, Inc. $131 1 payment
  11. Other $385 10 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,470 12 payments
  2. Travel and Lodging $13,209 74 payments
  3. Food and Beverage $11,618 263 payments
  4. Education $868 6 payments
Products named General payments · program years 2021–2025
  1. INTELLIS ADAPTIVESTIM $22,461 139 payments
  2. SYNCHROMEDII $11,083 51 payments
  3. HA MINUTEMAN G3-R $2,848 37 payments
  4. PAINTEQ $2,543 59 payments
  5. Senza $420 8 payments
  6. mild Device Kit $378 7 payments
  7. SPRINT PNS System $363 5 payments
  8. PROCLAIM $258 2 payments
  9. Superion Indirect Decompression System $178 4 payments
  10. ETERNA $173 2 payments
  11. Other $1,392 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

36

Median for Nurse Practitioner: 389

Drug cost

$1,049

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 24 $966
Methylprednisolone Generic 12 $84

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

355 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record